Immune-toxicity model and efficacy biomarkers enable precise NSCLC immunotherapy stratification
A new analysis of the phase 3 ORIENT-11 trial suggests that the future of lung-cancer immunotherapy may depend not only ...
A new analysis of the phase 3 ORIENT-11 trial suggests that the future of lung-cancer immunotherapy may depend not only ...
Gastric cancer has long presented oncologists with a difficult biological puzzle: two tumors that look similar under a microscope can ...
A team of researchers at The University of Texas MD Anderson Cancer Center has developed an innovative microfluidic platform named ...
Chimeric Antigen Receptor (CAR) T-cell therapy represents a groundbreaking paradigm in cancer treatment, offering a highly personalized approach to combating ...
In the evolving landscape of oncology, translating molecular biomarkers into actionable clinical decisions has become a critical frontier, particularly within ...
The University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), a leading National Cancer Institute (NCI)-designated comprehensive cancer center, has recently ...
In recent years, the landscape of cancer immunotherapy has been dramatically reshaped by the integration of cutting-edge genomic sequencing and ...
In a groundbreaking development for cancer treatment, the Ochsner MD Anderson Cancer Center located at The Gayle and Tom Benson ...
In a breakthrough that promises to revolutionize cancer immunotherapy and biomarker discovery, researchers have unveiled Pepyrus, a cutting-edge platform that ...
In recent years, the horizon of cancer treatment has been dramatically reshaped by groundbreaking advances in immunotherapy, with tumour-infiltrating lymphocyte ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine